ProMetic Life Sciences Inc. has received a $4.8 million purchase order under its ongoing supply agreement with Octapharma, a Swiss based plasma fractionation company that specializes in human proteins. The order relates to the purchase of PrioClear, a prion capture resin incorporated into Octapharma’s manufacturing process for its solvent/detergent treated plasma product, Octaplas. Octaplas is currently approved for marketing in the U.S. and several European countries. “This new pur...